Explore source-backed summaries of clinical research and official guidance. Check each article’s sources, publication date, review status, and correction notes.
FDA identifies potential safety risks for compounded BPC-157 and insufficient information to determine whether it would cause harm by the proposed routes of administration.
SURMOUNT-5 compared tirzepatide and semaglutide for weight loss in adults with obesity without diabetes. The open-label trial found greater average weight loss with tirzepatide at 72 weeks.
WADA’s prohibited list covers non-approved substances under S0 and specified peptide hormones, growth factors, and related substances under S2. Athletes should check the applicable list and their anti-doping organization’s guidance.
On March 8, 2024, FDA approved Wegovy injection to reduce cardiovascular death, heart attack, and stroke risk in adults with cardiovascular disease and either obesity or overweight.
